https://nevakarpharm.com/nevakar-announces-55-million-fundraising-press-release/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-featured-in-global-business-reports/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-featured-in-tech-news/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-and-endo-enter-into-exclusive-licensing-agreement-for-multiple-505b2-injectable-products/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-completes-30-million-financing-to-advance-pipeline-products/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-enters-50-million-product-financing-agreement-with-novaquest-capital-for-continued-development-of-injectable-products/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-enters-into-17-5-million-product-financing-agreement-with-h-i-g-capital-partners-for-continued-development-of-injectable-products/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-announces-fda-approval-for-ephedrine-sulfate-injection-as-ready-to-use-vials/2026-05-15T11:58:43-04:00https://nevakarpharm.com/industry-focus-a-look-at-nevakar/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-inc-announces-formation-of-nevakar-injectables/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-announces-closing-of-12-million-convertible-note-and-extension-of-interest-only-period-with-oxford-finance/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-injectables-announces-the-launch-of-ready-to-use-ephedrine-injection-vials/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-injectables-receives-u-s-fda-approval-of-ready-to-use-ephedrine-injection-in-a-prefilled-syringe/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-injectables-sells-six-development-stage-ready-to-use-injectable-product-candidates-to-endo-ventures-limited/2026-05-15T11:58:43-04:00https://nevakarpharm.com/nevakar-injectables-announces-fda-approval-of-cyclophosphamide-rtd-solution/2026-05-15T11:58:43-04:00